The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Beetham Thomas W. since 2020.
This trader's CIK number is 1741382.
At the time of last reporting, Beetham Thomas W. was the Chief Operating Officer of Viridian Therapeutics, Inc.\de. (stock ticker symbol VRDN).
Also see all insider trading activities at Viridian Therapeutics, Inc.\de.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | MGTA | 0 | $0 | 6,103 | $41,073 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | VRDN | 5,000 | $117,050 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | KNSA | 0 | $0 | 2,477 | $54,716 | 0 | $0 |
| 2020 | KNSA | 0 | $0 | 93,341 | $2,056,986 | 13,752 | $21,865 |
1. Dianthus Therapeutics, Inc. /de/ (MGTA)
2. Viridian Therapeutics, Inc.\de (VRDN)
3. Kiniksa Pharmaceuticals International, Plc (KNSA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-09-16 | MGTA | Sale | 6,103 | 6.73 | 41,073 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-09-27 | VRDN | Buy | 5,000 | 23.41 | 117,050 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-02-03 | KNSA | Sale | 2,477 | 22.09 | 54,716 |
| 2020-07-01 | KNSA | Sale | 29,589 | 25.58 | 756,886 |
| 2020-06-10 | KNSA | Option Ex | 13,752 | 1.59 | 21,865 |
| 2020-06-10 | KNSA | Sale | 13,752 | 25.07 | 344,762 |
| 2020-04-21 | KNSA | Sale | 2,518 | 20.00 | 50,360 |
| 2020-04-20 | KNSA | Sale | 47,423 | 19.06 | 903,882 |
| 2020-02-14 | KNSA | Sale | 59 | 18.58 | 1,096 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Beetham Thomas W. (Chief Operating Officer of Viridian Therapeutics, Inc.\de at the time of this reporting) see the Securities and Exchange Commission (SEC) website.